TEPANIL TEN-TAB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TEPANIL TEN-TAB (TEPANIL TEN-TAB).
TEPANIL TEN-TAB (diethylpropion hydrochloride controlled-release) is a sympathomimetic amine anorectic agent. It acts primarily on the central nervous system to suppress appetite, likely via stimulation of the hypothalamus to release norepinephrine and dopamine, leading to decreased food intake. The exact molecular mechanism involves inhibition of norepinephrine and dopamine reuptake in the synaptic cleft, increasing their concentrations in the central nervous system.
| Metabolism | Diethylpropion is extensively metabolized in the liver via N-dealkylation, hydroxylation, and conjugation. Major metabolites include ethylaminopropiophenone and other active metabolites. The cytochrome P450 enzyme system is involved, but specific isoforms have not been fully elucidated. |
| Excretion | Renal excretion accounts for 60-80% of the dose. Biliary/fecal elimination is approximately 10-20%. |
| Half-life | Terminal elimination half-life is 4-6 hours. Clinical context: Steady state is achieved within 1-2 days. |
| Protein binding | Plasma protein binding is 90-95%, primarily to albumin. |
| Volume of Distribution | Volume of distribution is 3-4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is 80-90% due to first-pass metabolism (approximately 5-10% metabolized). |
| Onset of Action | Oral immediate-release: 30-60 minutes. TEPANIL TEN-TAB (extended-release): 1-2 hours. |
| Duration of Action | Oral immediate-release: 4-6 hours. TEPANIL TEN-TAB: 8-12 hours due to extended-release formulation. |
| Molecular Weight | 210.2 |
25 mg orally three times daily, 1 hour before meals; for sustained-release, 75 mg orally once daily in the morning.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | Contraindicated in severe renal impairment (GFR <30 mL/min); no specific dose adjustment for mild-to-moderate impairment. |
| Liver impairment | Contraindicated in severe hepatic impairment; caution and reduced dose may be considered for Child-Pugh B or C, but no validated guidelines. |
| Pediatric use | Not recommended for patients under 16 years of age; safety and efficacy not established. |
| Geriatric use | Initiate at lower doses due to increased sensitivity; avoid use in elderly due to potential for adverse effects (cardiovascular, CNS stimulation, abuse liability). |
| 1st trimester | Contraindicated due to teratogenic effects in animal studies; avoid in first trimester. |
| 2nd trimester | Contraindicated due to risk of fetal pulmonary hypertension and neonatal withdrawal; avoid in second trimester. |
| 3rd trimester | Contraindicated due to risk of fetal pulmonary hypertension, premature delivery, and neonatal withdrawal; avoid in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for TEPANIL TEN-TAB (TEPANIL TEN-TAB).
| Placental transfer | Crosses placenta; detected in fetal plasma at concentrations similar to maternal levels. |
| Breastfeeding | Excreted in breast milk; may cause irritability and poor feeding in infants due to pharmacological effects; contraindicated in breastfeeding. |
■ FDA Black Box Warning
TEPANIL TEN-TAB has a high potential for abuse and dependence. It should not be used in combination with other anorectic agents or for long-term treatment. The drug is contraindicated in patients with a history of drug abuse.
| Serious Effects |
History of pulmonary arterial hypertensionConcurrent MAO inhibitor therapy or within 14 daysKnown hypersensitivity to diethylpropion or any componentHyperthyroidismCardiovascular disease including arrhythmias, coronary artery disease, and uncontrolled hypertensionAdvanced arteriosclerosisGlaucomaAgitated statesHistory of drug abusePregnancy and breastfeeding
| Precautions | Risk of serious cardiovascular events including hypertension, palpitations, tachycardia, and arrhythmias, Pulmonary hypertension reported, Seizures in epileptic patients, May impair ability to drive or operate machinery, Dependence and tolerance may develop, Use caution in patients with glaucoma, hyperthyroidism, or anxiety states, Monitor blood pressure and heart rate regularly |
| Food/Dietary | Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may enhance CNS stimulation. No specific food restrictions, but a calorie-restricted diet is essential for weight loss. |
Loading safety data…
| Lactation Rating |
| L5 - Contraindicated |
| Teratogenic Risk | First trimester: Limited human data; animal studies not adequate. Risk cannot be excluded. Second and third trimesters: Avoid use due to potential for fetal tachycardia, decreased fetal growth, and preterm labor. Anorexiants may cause fetal cocaine-like effects. Anorexiant use associated with increased risk of premature birth, low birth weight, and neonatal withdrawal (irritability, tremors). |
| Fetal Monitoring | Maternal: Heart rate, blood pressure, ECG if cardiac symptoms; monitor for pulmonary hypertension, valvular heart disease, and signs of abuse (tolerance, dependence). Fetal: Ultrasound for growth restriction if used in pregnancy; neonatal monitoring for withdrawal symptoms (hypertonia, tremor, poor feeding) if exposed near term. |
| Fertility Effects | Animal studies report no impairment of fertility at therapeutic doses. Human data lacking. Anorexiants may cause ovulatory dysfunction due to weight loss, but diethylpropion specifically not studied for fertility effects. |
| Clinical Pearls | TEPANIL TEN-TAB (diethylpropion hydrochloride) is a sympathomimetic anorectic used as a short-term adjunct in obesity management. Monitor for hypertension, tachycardia, and CNS stimulation. Avoid coadministration with MAOIs or within 14 days of their use. Risk of abuse and dependence; schedule IV controlled substance. Contraindicated in glaucoma, hyperthyroidism, agitated states, and history of drug abuse. |
| Patient Advice | Take this medication exactly as prescribed; do not increase dose or frequency. · Avoid taking late in the day to prevent insomnia. · Report any chest pain, shortness of breath, or severe headache immediately. · This medication may cause dizziness; avoid driving until you know how it affects you. · Do not stop abruptly; taper under medical supervision to avoid withdrawal. · Store at room temperature away from light and moisture. · Keep out of reach of children. |